Hidradenitis Suppurativa HSP90 Inhibition for Multi-Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hidradenitis suppurativa (HS) fail to uniformly downregulate inflammatory mediators such as IL-1b and the NLRP3 inflammasome, leading to ineffective management of the disease.
Innovation Solution
Administration of a compound of Formula I, such as CUDC-305, which is a potent inhibitor of heat shock protein 90 (HSP90), formulated in various pharmaceutical compositions for oral, topical, or parenteral delivery, to target and reduce inflammation in HS lesions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adalimumab and other current therapies target specific inflammatory cytokines, then specific inflammatory pathways are inhibited, but uniform downregulation of inflammatory mediators including IL-1b and NLRP3 inflammasome is not achieved
Solution Approach 1:
The patent employs HSP90 inhibitors that can simultaneously target multiple inflammatory mediators including IL-1b, NLRP3 inflammasome, and other cytokines through a single therapeutic agent. This multi-functional approach allows one compound to downregulate various inflammatory pathways uniformly, addressing the limitation of current single-target therapies while maintaining reliable treatment effectiveness
2Adaptability or versatility
If new therapies are developed to uniformly downregulate inflammatory mediators, then broad anti-inflammatory coverage is achieved, but treatment failure in response to current standard therapy remains common
Solution Approach 1:
The patent utilizes HSP90 inhibitors that fundamentally change the therapeutic parameter from cytokine-specific targeting to upstream protein folding inhibition. By targeting HSP90, a master regulator of protein conformation, the therapy achieves uniform downregulation of multiple inflammatory mediators simultaneously, thereby achieving both broad coverage and high treatment success rates
Data Source
AI summary
The present invention provides compositions and methods for treating hidradenitis suppurativa (HS) or an apocrine gland infection. In one embodiment, the invention provides a method for treating HS or an apocrine gland infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I),or a pharmaceutically acceptable salt thereof, wherein R is halogen, amino, —NH(C1-C3-alkyl) or —N(C1-C3-alkyl)2 and n is 1 or 2.